Drug Profile
DRGT 82
Alternative Names: DRGT-82Latest Information Update: 03 Sep 2020
Price :
$50
*
At a glance
- Originator Druggability Technologies
- Developer Tavanta Therapeutics
- Class Antineoplastics
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Renal cell carcinoma
Highest Development Phases
- No development reported Renal cell carcinoma
Most Recent Events
- 01 Sep 2020 Druggability Technologies is now called Tavanta Therapeutics
- 28 Aug 2020 No recent reports of development identified for preclinical development in Renal-cell-carcinoma in Ireland
- 26 Jul 2016 DRGT 82 is available for licensing as of 26 Jul 2016. http://www.drgtco.com/partnering/